Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer

被引：0
|
作者：
Rima Patel
Zhiqiang Li
Brittney S. Zimmerman
Marc Y. Fink
Jason D. Wells
Xiang Zhou
Kristin Ayers
Arielle Redfern
Scott Newman
Eric Schadt
William K. Oh
Rong Chen
Amy Tiersten
机构：
[1] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology
[2] Sema4,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 192卷
关键词：
Metastatic breast cancer; Obesity; Aromatase inhibitors; Hormone positive breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：313 / 319
页数：6
相关论文
共 50 条
  • [41] Tamoxifen or aromatase inhibitors in breast cancer : Efficacy and safety
    Neven, P.
    Van den Broecke, R.
    ACTA CHIRURGICA BELGICA, 2007, 107 (03) : 240 - 256
  • [42] Aromatase inhibitors in advanced breast cancer: there are efficacy differences
    A S Bhatnagar
    British Journal of Cancer, 2005, 92 : 1173 - 1174
  • [43] Aromatase inhibitors in advanced breast cancer: there are efficacy differences
    Bhatnagar, AS
    BRITISH JOURNAL OF CANCER, 2005, 92 (06) : 1173 - 1174
  • [44] Body mass index and prognosis in HER2-positive metastatic breast cancer patients
    Poletto, E.
    Minisini, A. M.
    Ferreira, A.
    Matteo, L.
    Poggio, F.
    Sottotetti, F.
    Montemurro, F.
    Pozzi, E.
    Rossi, V.
    Risi, E.
    Dellepiane, C.
    Sini, V.
    Ziliani, S.
    Minuti, G.
    Mura, S.
    Grasso, D.
    Bertolini, I.
    Del Mastro, L.
    Puglisi, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S285 - S286
  • [45] Effects of body mass index on the treatment outcome of patients with metastatic breast cancer in the real world
    Lee, Kyoung Eun
    Ham, Ahrong
    Lee, Sewon
    Jo, Jungmin
    Hong, Soo Ji
    Lee, Ji Eun
    Lee, Haena
    Gwark, Sungchan
    An, Jeongshin
    Kim, Hyun-Goo
    Lee, Jun Woo
    Woo, Joohyun
    Lim, Woosung
    Moon, Byung-In
    Ahn, Sei Hyun
    Lee, Hye Ah
    CANCER RESEARCH, 2024, 84 (09)
  • [46] The body mass index (BMI) and the effectiveness of the fulvestrant as treatment postmenopausal metastatic breast cancer patients
    Jagiello-Gruszfeld, A.
    Lemanska, I.
    Gorniak, A.
    Kunkiel, M.
    Glinka, E.
    Majstrak-Hulewska, A.
    Konieczna, A.
    Niwinska, A.
    Nowecki, Z.
    BREAST, 2019, 44 : S66 - S66
  • [47] Changes in body composition in early breast cancer patients treated with aromatase inhibitors
    Pedersini, R.
    Schivardi, G.
    Laini, L.
    Zamparini, M.
    Bonalumi, A.
    di Mauro, P.
    Bosio, S.
    Amoroso, V.
    Villa, N.
    Alberti, A.
    Di Meo, N.
    Gonano, C.
    Zanini, B.
    Lagana, M.
    Ippolito, G.
    Rinaudo, L.
    Farina, D.
    Castellano, M.
    Cappelli, C.
    Simoncini, E. L.
    Cosentini, D.
    Berruti, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (12) : 3119 - 3128
  • [48] Impact of Race and Body Mass Index on Breast Cancer Diagnoses
    Chung, Victoria
    Maini, Ruby
    Cattie, Rabia
    Olet, Susan
    Sheen, Melanie
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Fulvestrant in metastatic breast cancer previously treated with aromatase inhibitors
    Ribeiro, J.
    Luis, I.
    Fortunato, M.
    Correia, L.
    Quintela, A.
    Cortes, P.
    Costa, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 180 - 180
  • [50] Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer
    Glueck, Stefan
    von Minckwitz, Gunter
    Untch, Michael
    BREAST, 2013, 22 (02): : 142 - 149
12345